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Neuropathological ﬁndings in mitochondrial DNA disease vary and are often dependent on the type of mitochondrial DNA
defect. Many reports document neuronal cell loss, demyelination, gliosis and necrotic lesions in post-mortem material. However,
previous studies highlight vascular abnormalities in patients harbouring mitochondrial DNA defects, particularly in those with
the m.3243A4G mutation in whom stroke-like events are part of the mitochondrial encephalopathy lactic acidosis and
stroke-like episodes syndrome. We investigated microangiopathic changes in the cerebellum of 16 genetically and clinically
well-deﬁned patients. Respiratory chain deﬁciency, high levels of mutated mitochondrial DNA and increased mitochondrial mass
were present within the smooth muscle cells and endothelial cells comprising the vessel wall in patients. These changes were
not limited to those harbouring the m.3243A4G mutation frequently associated with mitochondrial encephalopathy, lactic
acidosis and stroke-like episodes, but were documented in patients harbouring m.8344A4G and autosomal recessive polymer-
ase (DNA directed), gamma (POLG) mutations. In 8 of the 16 patients, multiple ischaemic-like lesions occurred in the cerebellar
cortex suggestive of vascular smooth muscle cell dysfunction. Indeed, changes in vascular smooth muscle and endothelium
distribution and cell size are indicative of vascular cell loss. We found evidence of blood–brain barrier breakdown characterized
by plasma protein extravasation following ﬁbrinogen and IgG immunohistochemistry. Reduced immunoﬂuorescence was also
observed using markers for endothelial tight junctions providing further evidence in support of blood–brain barrier breakdown.
Understanding the structural and functional changes occurring in central nervous system microvessels in patients harbouring
mitochondrial DNA defects will provide an important insight into mechanisms of neurodegeneration in mitochondrial DNA
disease. Since therapeutic strategies targeting the central nervous system are limited, modulating vascular function presents an
exciting opportunity to lessen the burden of disease in these patients.
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Abbreviations: COX = cytochrome c oxidase; MELAS = mitochondrial encephalomyopathy with lactic acidosis and stroke-like epi-
sodes; ZO-1 = zona occludin-1
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Mitochondrial DNA diseases are a clinically heterogeneous group of
multisystem disorders, with neurological deﬁcits among the most
prominent and disabling features (DiMauro and Schon, 2008).
These neurological features typically include cerebellar ataxia,
epilepsy, peripheral neuropathy and dementia. Involvement of the
mitochondrial genome (mitochondrial DNA), whether due to pri-
marymitochondrialDNAmutations(suchaspointmutationsorcom-
plex rearrangements of mitochondrial DNA) or secondary
mitochondrial DNA defects, such as depletion or deletions, caused
by nuclear mutations, is frequently responsible for the development
of mitochondrial disease (Tuppen et al., 2010). A number of patho-
logical studieshavetriedtoexplain theunderlyingneuropathology in
these patients and these often include features of neuronal cell loss,
astrogliosis and white matter changes (Sparaco et al., 1993; Tanji
et al., 1999a, b).
The presence of cytochrome c oxidase (COX)-deﬁcient and/or
intensely succinate dehydrogenase reactive vessels containing
increased mitochondrial DNA copy number and enlarged mitochon-
dria on electron microscopy have been described in both non-CNS
and CNS tissues (Ohama et al., 1987, 1988; Hasegawa et al., 1991;
Tokunaga et al., 1993; Love and Hilton, 1996; Betts et al., 2006).
This increase in COX-deﬁciency has been attributed to a high muta-
tion load within the smooth muscle cells comprising the CNS vascu-
lature. Typically, these ﬁndings have been shown in patients
harbouring the common m.3243A4G mutation associated with
mitochondrial encephalomyopathy with lactic acidosis and
stroke-like episodes (MELAS) where stroke-like episodes are particu-
larly frequent (Betts et al., 2006). Additionally, Tanji et al. (2001)
have shown a decrease in the level of expression of mitochondrially
encodedCOXsubunitIIintheCNSmicrovasculatureofpatientswith
MELAS (Tanji et al., 2001).
The pathological consequences of the neurovascular
COX-deﬁciency are not well understood. Stroke-like episodes are
thought to contribute to the genesis of ischaemic-like lesions,
which typically manifest focally in the posterior cortical regions
of the brain (Sue et al., 1998). They resemble true infarcts in
that they are pan-necrotic and demonstrate profound neuronal
cell loss, microvacuolation, gliosis and eosinophilia in surviving
neurons but their topographical distribution does not follow the
vascular territories of major cerebral arteries or border zones.
Although stroke-like episodes are part of the clinical syndrome in
MELAS (Pavlakis et al., 1984), more recently stroke-like episodes
have been documented in patients harbouring the m.8344A4G
mutation associated with myoclonic epilepsy ragged red ﬁbres and
autosomal recessive mutations in the POLG gene encoding for
catalytic subunit of the polymerase gamma protein, which is re-
sponsible for mitochondrial DNA replication (Tanji et al., 2003;
Deschauer et al., 2007). Regions of necrotic cortical lesions with-
out clinical manifestation of stroke-like episodes has also been
seen in POLG mutations typically conﬁned to the posterior occipi-
tal lobe regions (Winterthun et al., 2005; Tzoulis et al., 2006,
2010).
Although the genesis of ischaemic-like lesions in mitochondrial
DNA disease is not well understood, a number of suggestions have
been proposed. These include the presence of dysfunctional mito-
chondria within the vessel wall, which might be causal for infarct
formation (Ohama et al., 1987; Hasegawa et al., 1991) with
treatment with L-arginine decreasing both the frequency and se-
verity of stroke-like episodes in MELAS (Koga et al., 2005, 2010).
Alternatively, energy failure within the neurons and glial cells is
primarily responsible for ischaemic-like lesions (Gilchrist et al.,
1996; Betts et al., 2006). Finally, neuronal hyperexcitability may
act as a trigger for the initiation of stroke-like episodes and there-
fore formation of lesions (Iizuka et al., 2002, 2003, 2007; Iizuka
and Sakai, 2005).
The principle aim of this study was to determine the extent of
vascular abnormalities in patients harbouring mitochondrial DNA
defects in the cerebellum, a region of the brain frequently involved
in patients with mitochondrial DNA disease. Previously, we have
shown that ataxia is a common symptom in patients with mito-
chondrial DNA disease and results from degeneration of the cere-
bellum (Lax et al., 2012a). The current study aimed to determine
whether the abnormalities of vasculature morphology and evi-
dence of respiratory chain deﬁciency correlated with the presence
of ischaemic-like lesions. In addition, we wanted to determine
which microvascular components demonstrated biochemical de-
fects and whether this correlated with the genetic defect. We
were able to show not only that the respiratory chain dysfunction
in smooth muscle and endothelial cells was associated with pres-
ence of ischaemic-like lesions but also, with breakdown of the
blood–brain barrier in areas not affected by lesions. Targeting
the blood vessel abnormalities may provide an important thera-
peutic approach for many patients with mitochondrial DNA
disease.
Materials and methods
Clinical details and
neurohistopathology
The patients included in this study consisted of 16 subjects with a
variety of primary or secondary mitochondrial DNA defects and ﬁve
age-matched, neurologically normal controls (Table 1). All control
cases were matched to patients for age, gender, post-mortem interval
and length of tissue ﬁxation. Local research ethical approval and full
consent for brain tissue retention and research was obtained and the
CNS tissues were processed by the Newcastle Brain Tissue Resource
(NBTR). Tissue processing and general neurohistopathological staining
was performed as previously described (Betts et al., 2006).
Immunohistochemistry using
chromogens
A range of primary antibodies (Supplementary Table 1) were used to
evaluate protein components comprising the mitochondrial respiratory
chain; including porin, complex I 20kDa, complex II 70kDa and com-
plex IV subunit I, vasculature markers; including smooth muscle cells,
endothelial cells, astrocytes and collagen IV and ﬁnally plasma
proteins; including ﬁbrinogen and IgG (detailed in Supplementary
Table 1). Serial sections of formalin-ﬁxed parafﬁn-embedded sagittal
cerebellum were cut at 5mm using a microtome (Microm International)
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.and mounted on to SuperFrost
TM slides (Thermo Fisher Scientiﬁc).
Immunohistochemical staining was performed as previously described
using a polymer detection system (Menarini Diagnostics) (Lax et al.,
2012b). Vascular markers for vascular smooth muscle cells, endothelial
cells and collagen IV were optimized using the avidin-biotin complex
(ABC) detection method. Brieﬂy, this involved deparafﬁnization and
rehydration of the tissue sections followed by antigen retrieval accord-
ing to the primary antibody used (Supplementary Table 1). Sections
were washed well in distilled water and incubated in 3% hydrogen
peroxide solution (Sigma) for 30min to block endogenous peroxidases.
The sections were then washed in Tris-buffered saline pH 7.4 and
blocked in 1% normal goat serum. The required primary antibody
was then applied at the appropriate dilution (Supplementary
Table 1) at room temperature for 90min. Following a Tris-buffered
saline pH 7.4 wash, biotinylated anti-mouse or anti-rabbit secondary
antibodies diluted 1:200 (Vector Laboratories) were then incubated
with the sections for 30min. This was followed by a Tris-buffered
saline pH 7.4 wash and application of the VECTASTAIN Elite ABC
(Vector Laboratories) for 30min. The sections were washed well in
distilled water before application of 3,30-diaminobenzadine (DAB;
Sigma) for 5min and a haematoxylin counterstain to allow visualiza-
tion of the marker of interest.
Quantitative measurement of
alpha-smooth muscle actin and collagen
IV immunoreactivity within arterioles
Quantitative measurements of collagen IV- and alpha-smooth muscle
actin-positive layers within the microvasculature were obtained from
controls (n=4) and patients harbouring m.3243A4G( n=4). Sections
(5-mm thick) stained for collagen IV or alpha-smooth muscle actin
were viewed on an Olympus microscope (Olympus BX54) under a
low magniﬁcation. The white matter of the cerebellum was outlined
using StereoInvestigator (MBF Bioscience) and a meander scan was
initiated throughout this region at  10 magniﬁcation. All arterioles
with a diameter 450mm were quantiﬁed by measuring the internal
and external diameter of the vessel wall which was immune-positive
for collagen IV or alpha-smooth muscle actin (modiﬁed from
Yamamoto et al., 2009). These measurements were performed three
times per vessel. The thickness of the alpha-smooth muscle actin- or
collagen IV immunopositive layer was then derived by the following
equation: layer thickness = (external diameter – internal diameter)/2.
A total of 86 and 134 collagen IV-positive and 77 and 192
alpha-smooth muscle actin-positive vessels were analysed in control
and m.3243A4G tissues, respectively. As the data were not normally
distributed, statistical signiﬁcance was assessed using GraphPad Prism
software (version 5, GraphPad Inc., http://www.graphpad.com/prism/)
using Kruskal Wallis with post hoc analysis performed using Dunn’s
multiple comparison test. Statistical signiﬁcance was determined when
P50.05.
Immunoﬂuorescence for identiﬁcation
of tight junctions
Dual immunoﬂuorescence was utilized to detect the endothelial cell
layer and tight junction proteins, zona occludin-1 (ZO-1) and occludin
in control (n=5), and patients with m.3243A4G( n=4) and
m.8344A4G( n=1). Patients were selected on the basis of the
COX-deﬁciency and pathological changes in the microvasculature.
Three 6mm formalin-ﬁxed parafﬁn-embedded sections were cut
at equally spaced intervals of a minimum of 25mm to enable
random sampling. These sections were deparafﬁnized and rehydrated
as described above. Heat-mediated antigen retrieval was performed by
microwaving sections in citrate buffer (pH 6). Sections were washed
well in distilled water and incubated with 3% normal goat serum
(Sigma) for 30min. The primary antibodies anti-GLUT1 and anti-ZO-
1 and anti-GLUT1 and anti-occludin were then applied at the optimal
dilution in 0.1% Triton-X and 1% normal oat serum Tris-buffered
saline solution (Supplementary Table 2) overnight at 4 C. The follow-
ing day, sections were washed three times for 5min with Tris-buffered
saline and incubated with the appropriate secondary antibodies
(Supplementary Table 2) for 1 h at 37 C. This was followed by
three 5-min washes with Tris-buffered saline. To amplify the signal
of tight junction primary antibodies, a biotinylated secondary antibody
was used and sections were incubated with Rhodamine-Red-X-
Streptavidin for 1h at 37 C (Supplementary Table 2). Finally, to min-
imize autoﬂuorescence the sections were incubated in 0.5% Sudan
black in 70% ethanol for 5min and rinsed in running tap water for
3min. Sections were coverslipped in hard-set mounting medium
(Vector Laboratories) and allowed to dry overnight at 4 C.
Analysis of immunoﬂuorescence
Images of the dual ﬂuorescently-stained sections were acquired using a
spinning disc confocal laser-scanning microscope (Zeiss) mounted on
an axio observer (C1, Zeiss) and equipped with AxioVision imaging
software (v.4.8). The images were captured at high magniﬁcation
using a  63/1.30 numerical aperture objective lens and a
Photometrix QuantEM
TM 512SC camera. Z-stacked imaging (three dif-
ferent levels, every 1.5mm) was carried out across the length, breadth
and depth of each specimen. Photographs were taken at these levels
with identical exposure times (400ms), gain and offsets used for each
image acquisition across conditions. Moreover, ﬂuorescent images
were always taken under identical conditions for laser excitation
(488 for FITC Alexa 488 green and 561 for rhodamine red) and emis-
sion (527/55nm and 645/60nm, respectively). Six random regions of
interest were identiﬁed per section.
Automated maximum intensity projection 16-bit (508   508 pixels)
ﬁle images were generated for each channel and imported into ImageJ
software (NIH). Blinded analysis was performed on the digital images
by tracing the outline of vessels manually. The integrated optical dens-
ity for individual vessels was calculated to represent the intensity of
ﬂuorescence for antibodies targeting GLUT-1, ZO-1 and occludin per
unit area outlined, in accordance with previously published protocols
(Fuseler et al., 2006, 2010; Guan et al., 2011).
All results were statistically analysed using GraphPad Prism soft-
ware (version 5, GraphPad Inc., http://www.graphpad.com/prism/).
The raw data values (given as ﬂuorescent intensity) for all three pro-
teins (GLUT1, ZO-1, occludin) failed a D’Agostino and Pearson omni-
bus normality test; thus data were analysed using non-parametric
tests. We tested for signiﬁcant differences between control groups
versus patients with m.3243A4G using a Kruskall–Wallis test followed
by a Dunn’s Multiple Comparison test. Analysis of the ﬂuorescence
intensity values for ZO-1 and occludin positive vessels between control
versus m.3243A4G vessels was performed using a Mann–Whitney
U-test. The results for the ﬂuorescence intensity analysis are given as
the means   standard deviation (SD).
Dual cytochrome c oxidase/succinate
dehydrogenase histochemistry
A dual histochemical assay for COX and succinate dehydrogen-
ase activities was used to identify COX-deﬁcient/succinate
CNS microangiopathy in mitochondrial DNA disease Brain 2012: 135; 1736–1750 | 1739dehydrogenase-positive cells within the vasculature. This was per-
formed on frozen 10mm cerebellum sections as previously described
(Betts et al., 2006).
Isolation of mitochondrial DNA from smooth
muscle cells
Vascular smooth muscle cells were visualized using an immunostaining
method designed to identify alpha-smooth muscle actin on frozen sec-
tions (20mm) mounted on polyethylene naphthalate-membrane slides
(Leica). Firstly, ﬁxation of the tissue was performed in cold acetone for
10min followed by incubation in 3% hydrogen peroxide for 20min
and incubation in 1% normal goat serum for 30min. Following this,
sections were incubated with a mouse anti-alpha smooth muscle actin
(Dako) diluted 1:1000 for 1h, followed by three 5-min washes with
Tris-buffered saline and incubation in biotinylated-secondary antibody
(goat anti-mouse IgG; Vector Laboratories) diluted 1:200 for 30min.
This was followed by three 5-min washes in Tris-buffered saline and
incubated in a VECTASTAIN Elite ABC solution (Vector Laboratories)
and visualized with 3,30-diaminobenzidene (Sigma). Sections were
dehydrated through ethanol (Alanar) series and stored at  20 C.
Isolation of the smooth muscle cell wall was performed using laser
microcapture dissection (Leica Microsystems LMD6000). Vascular
smooth muscle cell layers were selected based on staining and morph-
ology. Following capture, cells were lysed with a standard lysis buffer
overnight (Taylor et al., 2003).
Isolation of mitochondrial DNA from endothelial cells
The endothelium was visualized using a similar immunostaining proto-
col for identiﬁcation of smooth muscle cells. The main differences
included frozen sections (15mm) mounted on glass slides, the primary
antibody consisted of rabbit anti-GLUT1 (Fisher Scientiﬁc) diluted
1:300 and the secondary antibody consisted of a biotinylated goat
anti-rabbit IgG diluted 1:200 (Vector Laboratories). Antibody signal
was developed using the ABC kit and ﬁnally visualized with 3,30-dia-
minobenzidene (Sigma). Sections were dehydrated through an ethanol
(Alanar) series and stored in a 50% ethanol (Alanar) solution at 4 C.
Isolation of the endothelial cell layer was performed using a light
microscope with an attached micromanipulator (Leica). Vessel layers
were selected based on staining and morphology. Following cap-
ture, cells were lysed with a standard lysis buffer overnight (Taylor
et al., 2003).
Pyrosequencing to determine percentage heteroplasmy
level of mutated mitochondrial DNA
The quantitation of mutated mitochondrial DNA heteroplasmy
levels for point mutations including m.3243A4G, m.8344A4G
and m.13094T4C was performed using PyroMark
TM Q24
platform (Qiagen) as previously described (Alston et al., 2010; Lax
et al., 2012a).
Quantitative real-time polymerase
chain reaction
A multiplex real-time PCR MT-ND1/MT-ND4 assay was used to quan-
tify the levels of mitochondrial DNA deletions in isolated vessels
according to previously described methods (Bender et al., 2006;
Krishnan et al., 2007).
Results
Neurohistopathology of the
microvasculature
In the current study, 8 out of 16 patients demonstrated evidence
of multiple, pan-necrotic lesions in the posterior inferior cerebellar
cortex characterized by tissue destruction as well as neuronal
cell loss. Typically, lesions occurred in patients harbouring the
m.3243A4G (6/7 patients) and m.8344A4G (1/1 patient)
point mutations and autosomal recessive p.Ala467Thr and
p.Trp748Ser POLG mutations (1/1 patient) (Table 2). This is
exempliﬁed by Fig. 1 where a control cerebellar cortex is shown
(Fig. 1A) relative to patient with m.3243A4G cerebellar cortex
(Fig. 1B) affected by a ischaemic-like lesion involving the molecu-
lar, Purkinje cell and granular cell layers. In addition, microvascular
mineralization was observed in two patients with m.3243A4G,
predominantly in the arterioles within the deep white matter of
the cerebellum (Fig. 1C and D). No morphological changes to the
white matter myelin components were detected around the
affected microvasculature.
Table 2 Summary of the vascular abnormalities occurring in the cerebellum of patients with mitochondrial DNA defects
P t1 P t2 P t3 P t4 P t5 P t6 P t7 P t8 P t9 P t1 0 P t1 1 P t1 2 P t1 3 P t1 4 P t1 5 P t1 6
Frozen tissue available for analysis +   +   +++++ + + + + + +
Evidence of vascular COX-deﬁciency + ND ND + ND +++++    ND   
Fixed tissue available for analysis ++++ +++  +   +++  +  
Presence of microinfarct ++++   ++           
Presence of vessel mineralisation       ++           
Deposition of collagen IV " $$" $ND *" ND " ND "$ ND ND ND ND
Mitochondrial density in vasculature """" "#ND ND " ND """#$ "
Extravascular plasma proteins ND +   + ++++N D N D N D N D  +N D
Neuronal/glial uptake of plasma proteins ND +   ++   +   ND ND ND ND +   +N D
Purkinje cells immunoreactivity (%) ND 1 0 60–70 50 0 30 0 ND ND ND ND 20 0 50 ND
+ = present;   = absent; " = increased; # = - decreased; $ = no change; ND = not determined (due to lack of tissue); Pt = Patient.
1740 | Brain 2012: 135; 1736–1750 N.Z. Lax et al.Figure 1 Pathological changes in small vessel morphology are observed in the cerebellum. Relative to control (A; haematoxylin and
eosin), the cerebellar cortex of a patient harbouring m.3243A4G shows evidence of an ischaemic-like lesion involving the molecular,
Purkinje cell and granular cell layers and the underlying white matter (B; Patient 6; haematoxylin and eosin). Arteriole mineralization is
prominent in patients harbouring the m.3243A4G mutation (C and D; Patients 6 and 7; haematoxylin and eosin). Relative to control
vessels (E; collagen IV), numerous patient vessels show increased deposition of collagen IV (F; Patient 7; collagen IV). Quantitation of the
collagen IV immunopositive layer reveals a signiﬁcant increase in collagen IV within the basement membrane of arterioles from patients
with the m.3243A4G mutation relative to control vessels (G; ***P50.0001). Scale bars = 100mm.
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We also documented changes in the pattern of collagen IV stain-
ing in those patients demonstrating vascular COX-deﬁciency
(Table 2). Typically an increase in collagen IV deposition in the
basement membrane was observed (Fig. 1E and F). Indeed quan-
titation of the thickness of the collagen IV immunopositive
layer within arterioles demonstrated a signiﬁcant increase in
patients harbouring the m.3243A4G mutation relative to controls
(Fig. 1G; P50.0001).
Mitochondrial dysfunction in the microvasculature
All controls used in this analysis demonstrated normal COX activity
(Fig. 2A). However, widespread vascular COX-deﬁciency was
detected in patients harbouring the m.3243A4G (Fig. 2B; n=4)
and m.8344A4G (Fig. 2C; n=2) point mutations. This was most
prominent in the white matter arterioles, where COX-deﬁciency was
present in both the vascular smooth muscle cell and endothelial cell
layers, but was also detected in the meninge vessels (Fig. 2B).
Interestingly, two patients (Patients 4 and 7) demonstrated striking
COX-deﬁciency in the endothelial cells of capillaries throughout the
dentate nucleus, while the dentate neuronal cell populations re-
vealed intact COX activity (Fig. 2D). COX activity was normal in
the microvasculature of control cases and patients harbouring the
m.13094T4C mutation (Patient 11), a single large-scale mitochon-
drial DNA deletion (Patient 14) and recessive POLG mutations
(Patients 16 and 17). Unfortunately due to unavailability of frozen
tissue, some patients could not be assessed for COX activity (e.g.
Figure 2 Mitochondrial dysfunction is prominent in patients harbouring m.3243A4G and m.8344A4G point mutations. Relative to
control vessels (A), COX-deﬁciency within the smooth muscle and endothelial cell layers was evident in cerebellar white and grey matter
arterioles of patients with the m.3243A4G( B; Patient 7; COX-succinate dehydrogenase) and the m.8344A4G( C; Patient 9,
COX-succinate dehydrogenase) mutations. Typically, capillary COX-deﬁciency was marked relative to dentate neurons where COX
activity was intact (D; Patient 7, COX-succinate dehydrogenase). Relative to white matter vessels in controls (E), mitochondrial density
was increased in many vessels of the patients with mitochondrial DNA disease (F, Patient 5, Porin immunohistochemistry). Scale
bars = 100mm.
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ischaemic-lesions were detected (Table 2).
Combined immunohistochemistry and histochemistry using mar-
kers of mitochondrial mass, including anti-porin, anti-complex II
70kDa and succinate dehydrogenase activity, indicated a higher
density of mitochondria localized within the vasculature in the
majority of patients relative to controls (Fig. 2E and F; Table 2).
This was observed in 10/13 patients and included m.3243A4G,
m.8344A4G and intriguingly, those patients without evidence
of COX-deﬁciency including those with m.13094T4C and
m.14709T4C point mutations, single large-scale mitochondrial
DNA deletion and recessive POLG mutations.
Morphology of the neurovascular unit
All patients were investigated using immunohistochemical markers
for vascular smooth muscle and endothelial cells to evaluate any
changes in cellular morphology throughout the cerebellum.
Evidence of vascular smooth muscle cell loss was observed with
thinning of the vascular smooth muscle cell layer in m.3243A4G
(2/3 patients), m.8344A4G (1/1 patient) and m.13094T4C
(Fig. 3A). Typically, the vascular smooth muscle cell layer demon-
strated a granular, fragmented appearance in the patients with
m.3243A4G and m.8344A4G mutations with a decrease in
immunoreactivity indicative of vascular smooth muscle cell loss
[Fig. 3A(ii and iii)]. Quantitation of alpha-smooth muscle actin
immunopositive layer revealed a statistically signiﬁcant reduction in
the thickness of this layer in patients harbouring the m.3243A4G
mutation relative to control cases (Fig. 3D; P50.0001). Evidence
of endothelial cell loss was observed with a number of arterioles
showing thinning of this layer in patients harbouring m.3243A4G
and m.8344A4G [Fig. 3B(i–iii)]. Assessment of the density of
astrocytic foot processes surrounding arterioles did not appear to
differ between our patients and control cases [Fig. 3C(i–iii)].
High heteroplasmy levels of mutated
mitochondrial DNA in the vessel wall
Molecular analysis of the vascular smooth muscle cell and endo-
thelial cell layers of cases with available frozen tissues revealed
high percentage levels of mutated mitochondrial DNA in patients
with point mutations (Table 3). Typically, patients with the highest
(470%) level of mutated mitochondrial DNA also demonstrated
vascular COX-deﬁciency. These data are in agreement with the
segregation of the mutation with the biochemical defect. Skeletal
muscle mitochondrial DNA heteroplasmy levels are given as a
comparison in Table 3, showing similar levels in skeletal muscle,
vascular smooth muscle and endothelial cells.
Immunoﬂuorescent evaluation of the
endothelium and tight junction proteins
Immunoﬂuorescent analysis of the endothelium and tight junction
proteins was performed on tissues from patients harbouring
m.3243A4G( n=4) and m.8344A4G( n=1) relative to
age-matched control cases (n=4). Since these cases demonstrated
vascular COX-deﬁciency and morphological changes in the vessel
wall, tight junction proteins were assessed as they are known to
be affected when the blood–brain barrier is compromised.
Evaluation of tight junction morphology and distribution in control
cases revealed ﬁlamentous immunoreactivity along the vessel
endothelium (Fig. 4A–L). In contrast, those patients harbouring
the m.3243A4G mutation revealed a redistribution of both
ZO-1 and occludin with extrusion of these proteins from the
vessel wall into the CNS microenvironment. This was accompanied
by obvious thinning and fragmentation of the tight junction pro-
teins (Fig. 4M–X). Evaluation of the tight junction protein expres-
sion, ZO-1 and occludin revealed lower ﬂuorescence intensity in
m.3243A4G and m.8344A4G relative to control cases (Table 4).
This was a signiﬁcant reduction in ﬂuorescence intensity in
m.3243A4G for both ZO-1 and occludin relative to controls
(P50.0001 and P50.0001, respectively). The lowered ﬂuores-
cence intensity for ZO-1 and occludin was also observed in
m.8344A4G (Table 4 and Fig. 5).
Assessment of the endothelium using GLUT1 showed fragmen-
tation of the endothelial cell layer. Indeed quantitation of
immunoﬂuorescent intensity revealed a signiﬁcant reduction in
ﬂuorescence intensity in all m.3243A4G patients assessed relative
to control cases (P50.001, Figs. 4 and 5). Similar levels of GLUT1
ﬂuorescence intensity were detected in a patient harbouring
m.8344A4G mutations (Fig. 5 and Table 4). A lowered GLUT1
ﬂuorescence intensity indicates a loss of the endothelium consist-
ent with the immunohistochemistry ﬁndings described earlier.
Plasma protein extravasation associated
with m.3243A4G and m.8344A4G
Assessment of ﬁbrinogen and IgG in control tissue showed no
extravasation of ﬁbrinogen surrounding vessels. However, evi-
dence of Purkinje cell immunoreactivity to ﬁbrinogen and IgG
was observed in 4/6 control cases, while the dentate nucleus
was spared. In the remaining two cases there was no neuronal
immunoreactivity of either Purkinje cells or dentate neurons
[Fig. 6A(i and ii)].
The presence of extravascular plasma proteins was observed in
all patients demonstrating vascular COX-deﬁciency and thinning
of the endothelial cell layer. Leakage of plasma proteins, including
ﬁbrinogen and IgG into the brain microenvironment was observed
in patients with m.3243A4G and m.8344A4G mutations.
Evaluation of unaffected regions showed weak immunoreactivity
for ﬁbrinogen in the neuropil of the white or grey matter depend-
ing on the location of the leaky vessel. In general, neurons and
glia immunoreactive to ﬁbrinogen and IgG could be detected in
the vicinity of the leaky vessels, indicative of neuronal and glial
uptake of the plasma proteins. All patients harbouring the
m.3243A4G mutation, excluding Patient 3, showed extravasation
of ﬁbrinogen, and to a lesser extent IgG; this was accompanied by
immunoreactive Purkinje cells indicating neuronal uptake
(Table 2). Patient 9 (m.8344A4G mutation) also showed extrava-
sation and Purkinje cell uptake [Fig. 6B(i and ii); Table 4]. Patients
with mitochondrial DNA mutations other than m.3243A4Go r
m.8344A4G demonstrated comparable levels of immunoreactive
Purkinje cells to control cases. A number of patients could not be
CNS microangiopathy in mitochondrial DNA disease Brain 2012: 135; 1736–1750 | 1743Figure 3 Thinning of vascular smooth muscle and endothelial cell layers in arterioles and high levels of mitochondrial DNA mutation.
Relative to vessels in normal controls [A(i)]; alpha-smooth muscle actin immunohistochemistry), there is thinning of the vascular smooth
muscle cell layer in many patients, particularly those harbouring the m.3243A4G mutation including Patient 1 [A(ii)] and Patient 6
[A(iii)]. In contrast to control [B(i)]; GLUT1 immunohistochemistry), there is also thinning of the endothelial cell layer in numerous
patients, including Patient 2 [B(ii)] and Patient 7 [B(iii)]. Cerebellar vessels in controls [C(i)]; glial ﬁbrillary acidic protein immunohisto-
chemistry) and patients (Patient 6, [C(ii)]; Patient 7, [C(iii)] demonstrate similarly high density of the surrounding astrocytic foot processes.
Quantitation of the alpha-smooth muscle actin immunopositive layer shows a signiﬁcant reduction in thickness in patient arterioles relative
to control arterioles (D; ***P50.0001). Scale bars = 100mm.
Table 3 Per cent level mutated mitochondrial DNA in vascular smooth muscle cells, endothelial cells and skeletal muscle
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
VSMC (%) 72 ND ND 84 ND 84 76 80 92 88 51 ND 51 ND 22 28
GLUT1 (%) 71 ND ND 86 ND 88 87 82 90 86 48 ND 58 42 19 51
Skeletal muscle (%) 72 ND ND 64 ND 63 72 85 ND 91 83 100 40 ND ND ND
ND = not determined; VSMC = vascular smooth muscle cells.
1744 | Brain 2012: 135; 1736–1750 N.Z. Lax et al.included for analysis due to insufﬁcient tissue sections available for
immunostaining.
Extravascular ﬁbrinogen immunoreactivity was also seen dif-
fusely throughout the pan-necrotic lesions of the cerebellar
cortex in Patients 4 and 7 (Fig. 6C). In addition to this diffuse
expression in the cortex, Purkinje cell and glial cell immunoreac-
tivity was demonstrated suggesting uptake of plasma proteins in
these cells [Fig. 6C(i)]. Neighbouring arterioles also showed
ﬁbrinogen leakage with intense immunoreactivity in astroglia
[Fig. 6C(ii)].
Discussion
Our study conﬁrms that vascular respiratory deﬁciency occurs in
the microvasculature throughout the cerebellum in patients with
speciﬁc mitochondrial DNA point mutations. While this is particu-
larly prominent in patients harbouring the common m.3243A4G
mutation, it is also observed in other patients with other mito-
chondrial DNA point mutations. In the current study, we have
investigated 16 patients to show that vascular respiratory chain
deﬁciency is positively correlated with additional vascular path-
ology including excess deposition of perivascular collagen and
thinning of the vessel wall. We show that there is good correlation
between the level of mitochondrial DNA mutation and the devel-
opment of respiratory chain deﬁciency. We reveal that the respira-
tory defect is not limited to vascular smooth muscle cell layer but
also involves the endothelial cells, which might be responsible for
the structural changes observed in the vessel walls and also break-
down of the blood–brain barrier. From these data, we postulate
that microangiopathic changes in the cerebellum occur due to the
presence of high levels of mutated mitochondrial DNA and
respiratory deﬁciency within the vessel walls and contribute to
the formation of pan-necrotic lesions that play an important role
in the genesis of ataxia.
Respiratory chain deﬁciency in the CNS microvasculature has
been reported previously in patients with MELAS and Kearns–
Sayre syndrome (Tanji et al., 2001; Betts et al., 2006). Here, we
show that respiratory chain deﬁciency, as judged by COX/succin-
ate dehydrogenase histochemistry, is most notable in the arterioles
supplying the cerebellum of patients harbouring m.3243A4G and
m.8344A4G point mutations. In these patients, vascular respira-
tory deﬁciency far outweighs any neuronal respiratory deﬁciency
Figure 4 Immunoﬂuorescent images of patient and control
cerebellum microvessels, which illustrate the expression and
localization of dual-stained endothelium and tight junction pro-
teins. Images from control tissue show the tightly sealed
monolayer of the microvascular endothelium, identiﬁed by
immunoﬂuorescently labeled GLUT1 (B, E, H and K; green) and
co-stained for tight junction proteins, ZO-1 (A and G; red) or
occludin (D and J; red). The distribution of ZO-1 and GLUT1 (C
and I) or occludin and GLUT1 (F and L) can be observed in
merged images. BBB pathology is observed in patients har-
bouring the m.3243A>G mutation. In these patients, there is an
absence of an intact GLUT1-positive matrix interna (N, Q, T and
W; highlighted by yellow star) with evidence of increased frag-
mentation, decreased immunoreactivity for GLUT1, and
increased gap widening between adjacent single endothelial
contact points (N, Q and T; yellow arrowheads). In contrast, the
control microvessels appear to have an intact and continuous
ring of GLUT1-positive endothelial cells within the internal
milleau of the microvasculature (B, E, H and K; white arrow-
heads). Disrupted expression of TJ proteins was observed in
patients with m.3243A>G compared to controls, including dis-
continuous staining of ZO-1 (M; yellow arrowhead and S) and
occludin (P and V; yellow arrowhead). There appears to be
increased ﬁltration of these proteins into the brain parenchyma
which can be seen on merged images of ZO-1 and GLUT1
(O and U) or occludin and GLUT1 (R and X) which was absent in
Figure 4 Continued
control cases. These pathological signs were consistent with the
results obtained from quantifying GLUT1 and TJ protein immu-
noﬂuorescence, where lower expression levels were demon-
strated in patients versus controls. The images were compiled
from control and m.3243A>G cerebellum using a x100, oil-
based objective and a confocal z-series stack taken every 260nm
throughout the depth of the entire section (6mm). Images were
then deconvolved using Huygens (SVI, v 3.7.1 The
Netherlands), with maximum intensity projections rendered in
ImageJ. Scale bar = 5–10mm.
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ing neuronal populations.
In addition to respiratory deﬁciency, we observe increased mito-
chondrial density in the microvasculature. This has been described
before in ultrastructural, histochemical and in situ hybridization
studies where an aggregation of enlarged mitochondria within
the vascular smooth muscle cell and endothelial cell layers are
observed (Ohama et al., 1987; Sakuta and Nonaka, 1989;
Hasegawa et al., 1991; Love and Hilton, 1996; Betts et al.,
2006). Histochemically, these vessels have been termed ‘strongly,
succinate dehydrogenase-reactive’ since they are COX-deﬁcient,
but intensely succinate dehydrogenase-reactive. It has been pro-
posed that accumulation of these abnormal mitochondria might
lead to occlusion of the vessel and restrict blood ﬂow (Sakuta
and Nonaka, 1989). However, we believe it is more likely to be
secondary phenomena due to high mutation heteroplasmy levels
Figure 5 Quantiﬁcation of the degree of immunoreactivity/expression of tight junction proteins ZO-1 and occludin, and the level of the
endothelial marker GLUT1 in the deep white matter of the cerebellum that had been co-expressed with the relevant tight junction protein.
Mean ﬂuorescence intensity (FI; in percentage) of ZO-1 co-expressed with GLUT1 in vessels of patients harbouring m.3243A4G and
m.8344A4G mutations normalized to control tissue (A). Mean ﬂuorescence intensity (in percentage) of occludin co-expressed with
GLUT1 in m.3243A4G and m.8344A4G specimens normalized to control tissue (B). In each case, the mean control ﬂuorescence intensity
was calculated as 100% (mean   SD). Statistically signiﬁcant differences between control and m.3243A4G vessels were detected by
using the Wilcoxon-Rank Sum Test. Changes in mean ﬂuorescence intensity were detected as highly signiﬁcant for all proteins examined
(*P50.05).
Table 4 Mean Immunoﬂuorescence intensity values given   standard deviations for GLUT1, ZO-1 and occludin
Protein Control cases (n = 5) m.3243A4G( n = 4) m.8344A4G( n =1 )
ZO-1 158.2   10
6   39.9   10
6 100.9   10
6   23.4   10
6 116.2   10
6   34.7   10
6
GLUT1 185.0   10
6   94.1   10
6 75.1   10
6   31.2   10
6 73.0   10
6   34.7   10
6
Occludin 184.4   10
6   24.1   10
6 84.8   10
6   31.7   10
6 105.2   10
6   62.0   10
6
GLUT1 165.2   10
6   73.4   10
6 89.8   10
6   20.7   10
6 61.7   10
6   42.5   10
6
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chondria proliferate, in response to respiratory defects, in order to
maintain biochemical activity. This is similar to the ragged red
changes frequently observed in skeletal muscle biopsies from
these patients.
We observe additional vessel pathology with evidence of arteri-
ole mineralization, which has been described in neuroradiological
studies in relation to mitochondrial DNA disease and ageing (Sue
et al., 1998; Ostling et al., 2003). The precise mechanisms of
mineralization are not well understood; however, it has been pos-
tulated that vascular smooth muscle cell dysfunction is the main
driving force for mineralization (Speer et al., 2009). This is a par-
ticularly intriguing suggestion since we observe high levels of mito-
chondrial DNA mutations and respiratory deﬁciency in the vascular
smooth muscle cell layer and immunohistochemical evidence of a
loss of vascular smooth muscle cells from the arteriole wall. The
Figure 6 Evidence of blood–brain barrier dysfunction was observed in many patients with extravasation of plasma proteins. Fibrinogen
immunohistochemistry in control tissues demonstrated a lack of immunoreactivity in Purkinje cells [A(i)] and dentate nucleus neurons
[A(ii)], while evaluation of a patient with m.8344A4G shows evidence of immunopositive Purkinje cells [B(i)], Patient 10) and dentate
nucleus neurons [B(ii)]. Extravasation of ﬁbrinogen was demonstrated in an ischaemic-like lesion in the cerebellar cortex of Patient 4
(C; ﬁbrinogen). Examination at a higher magniﬁcation reveals evidence of Purkinje cell uptake [C(i)] and immunoreactivity within the
molecular and granular cell layers is observed [C(i)]. In the adjacent white matter [C(ii)], a vessel showing immunoreactivity for ﬁbrinogen
is surrounded by immunopositive glial cells. Scale bars = 100mm.
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tenance of vascular tone and therefore regulate blood ﬂow. If
these cells are energetically compromised, this could perturb vas-
cular tone and impede the ability of the vascular smooth muscle
cells to adapt to alteration in the microenvironment, also known as
functional hyperaemia. Further evidence in support of impaired
vascular tone may derive from our observed increase in collagen
IV immunoreactivity in the microvasculature indicating an increase
in the thickness of the basement membrane and hyalinosis, which
might be related to endothelial cell and vascular smooth muscle
cell dysfunction.
Marked reduction in endothelial cell thickness and fragmenta-
tion of this cell layer is seen in patients exhibiting vascular
COX-deﬁciency. The CNS endothelium plays an essential role in
maintaining integrity of the blood–brain barrier and preventing
harmful substances from reaching neuronal cells (Bradbury,
1993). It achieves this by way of a continuous ring of tight junc-
tion proteins that are situated between adjacent endothelial cells.
Here, we show a loss of two key tight junction proteins, ZO-1 and
occludin, in those patients demonstrating high levels of
m.3243A4G and m.8344A4G mitochondrial DNA mutations,
COX-deﬁciency and abnormal vessel morphology. Growing evi-
dence suggests that an impairment of the blood–brain barrier cor-
relates with a decrease of tight junctions in the endothelial layer
(Clatterbuck et al., 2001; Glading et al., 2007). In conjunction
with this, there is extrusion of plasma proteins into the brain par-
enchyma providing further evidence of compromised blood–brain
barrier associated with m.3243A4G and m.8344A4G mutations
in agreement with earlier ﬁndings in a patient with MELAS (Tanji
et al., 2001). A recent in vitro blood–brain barrier model consist-
ing of CNS astrocytes and endothelial cells has shown that in the
presence of high levels of the m.3243A4G mutation, the blood–
brain barrier becomes compromised. They showed that the endo-
thelial cells demonstrate COX-deﬁciency and also have markedly
lowered trans-endothelial electrical resistance suggesting an in-
crease in blood–brain barrier permeability (Davidson et al.,
2009). The contribution of blood–brain barrier dysfunction due
to mitochondrial DNA defects to neurodegeneration remains to
be elucidated; however, extravasation of plasma proteins might
present an extra burden on neural function. This is an important
area of investigation since blood–brain barrier dysfunction has
been documented in other mitochondrial DNA disorders, including
mitochondrial neurogastrointestinal encephalopathy (MNGIE)
(Szigeti et al., 2004).
Our study shows that pan-necrotic lesions are common in the
cerebellum of patients with mitochondrial DNA point mutations
(m.3243A4G and m.8344A4G) and nuclear mutations in
POLG causing secondary defects of the mitochondrial DNA. In
association with this, there is evidence of vascular COX-deﬁciency
involving all arterioles and changes in the density of vascular
smooth muscle cell and endothelial cells. How these deﬁciencies
contribute to the focal vascular events is uncertain. We certainly
do not detect any evidence of occlusion and in our view the vas-
cular smooth muscle deﬁciency is likely to lead to impaired regu-
lation of blood supply and local ischaemia due to an absent
response to localized changes in energy demand. This is a feasible
hypothesis since smooth muscle dysfunction in the bowel wall of
patients with m.3243A4G is thought to be the cause of bowel
dysmotility in these patients (Betts et al., 2008). In addition to the
vascular smooth muscle cell pathology, respiratory deﬁciency
observed in endothelial cells might affect the formation of tight
junction and therefore impair cell–cell contacts resulting in blood–
brain barrier breakdown. Blood–brain barrier disruption might pre-
sent an additional strain on neighbouring neurons and glial cells
since they appear to actively uptake plasma protein components
to remove them from the brain microenvironment (Matz et al.,
2001). It has been suggested that uptake by neurons and astro-
cytes may merely represent post-mortem changes in blood–brain
barrier permeability (Mori et al., 1991; Munoz et al., 1997); how-
ever, plasma protein extravasation was much higher in patient
tissues compared to control indicating that changes in localization
of ﬁbrinogen and IgG are true pathological alterations. In fact, a
recent study links ﬁbrinogen leakage into the brain parenchyma
with neuronal damage in Alzheimer’s disease (Cortes-Canteli
et al., 2010).
This study expands on the complicated story of neurodegenera-
tion in mitochondrial DNA disease where multiple mechanisms
likely exist to contribute to dysfunction and degeneration of the
CNS. Critically, this study shows respiratory deﬁciency in vessels
from patients with other mitochondrial DNA mutations, not just
m.3243A4G and the extent to which the microvasculature is
pathologically affected. This area of neurodegeneration is import-
ant since the microvasculature might present a feasible target
for therapeutic intervention and thus modulation of disease
progression.
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